InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Cover Story

  • IP under threat from competition clampdown

    From pharmaceuticals to telecoms, software and even copyright licensing, antitrust authorities are clamping down on abuses of IP rights. James Nurton, Eileen McDermott and Peter Ollier examine why IP is under scrutiny and discuss some pending cases and investigations

Features

Survey

  • Copyright survey results

    Top copyright firms ranked in 19 jurisdictions. Plus: Eileen McDermott explores some areas in which the internet has highlighted a need for change in copyright law

IP Clinic

  • Should we embrace viral marketing?

    My company is about to launch an advertising campaign, and we think it could become very popular. Should we welcome this and are there are any particular trade mark/branding concerns we should be aware of?

Diary

  • Utynam's Heirs

    A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam - who received the world’s first recorded patent in 1449

Country Updates

profile

Managing IP

ManagingIP

ManagingIP profile

David Knight of @Fieldfisher discussing the Big Bus patent licence case (he's on the right) http://t.co/XqcyJBPR6W http://t.co/38Mc7eXLf5

Jul 2 2015 04:25 ·  reply ·  retweet ·  favourite
ManagingIP profile

Mike Lawrence of JTL Systems is demonstrating some of his inventions at @Fieldfisher patent seminar http://t.co/5JIbvqC2Os

Jul 2 2015 02:39 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @EPOorg: The public can now nominate an #inventor for the European Inventor Award 2016! Please spread the word: http://t.co/LRR4qwI4He #…

Jul 2 2015 12:41 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements